论文部分内容阅读
目的探讨流式细胞术(FCM)检测肿瘤相关基因P16蛋白表达的应用价值。方法用人白细胞共同抗原45(CD45)和P16荧光标记抗体同步标记肺穿刺肿瘤标本中血细胞和肿瘤细胞的P16蛋白,经FCM测定CD45+P16+和CD45-P16+细胞比率后,对每份穿刺标本血细胞P16+与肿瘤细胞P16+细胞的比值(r)进行比较。结果肺癌患者39份穿刺标本中正常血细胞与肿瘤细胞的P16蛋白低表达率分别是15·39%(6/39)和69·23%(27/39),二者差异有统计学意义(P<0·05)。61·90%(13/21)的异倍体肿瘤r>4;22·22%(4/18)的二倍体肿瘤r>4,两组间差异有统计学意义(P<0·05)。结论FCM可同步测定血细胞与肿瘤细胞P16蛋白表达水平,并可比较区分出表达程度的差异性,在临床科研应用中有较好的前景。
Objective To investigate the value of flow cytometry (FCM) in the detection of tumor-related gene P16 protein expression. Methods The P16 protein of blood cells and tumor cells in lung biopsy specimens were simultaneously labeled with human leukocyte common antigen 45 (CD45) and P16 fluorescent labeled antibody. The percentage of CD45 + P16 + and CD45-P16 + cells was determined by FCM. And tumor cell P16 + cell ratio (r) were compared. Results The low expression rates of P16 protein in normal blood cells and tumor cells in 39 samples of lung cancer patients were 15 · 39% (6/39) and 69 · 23% (27/39), respectively, with significant difference (P <0 · 05). 61.9% (13/21) of aneuploid tumors were r> 4; 22.22% (4/18) of diploid tumors were r> 4, with significant difference between the two groups (P <0.05) ). Conclusion FCM can synchronously determine the expression of P16 protein in blood cells and tumor cells, and can be used to distinguish the difference of expression level between P16 protein and FCM. It has a good prospect in clinical research.